1Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation
Trust, Bristol, 2Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds …

The article presents the revised and updated guidelines on the diagnosis and management
of multiple myeloma. It includes new sections on imaging and the management skeletal …

Recommendations are based on a review of the literature using Medline, PubMed, Embase,
Central, Web of Science searches from the beginning of 2013 up to July 2019. The following …

We compared antithymocyte globulin (ATG) with alemtuzumab in 73 patients with multiple
myeloma, who underwent reduced conditioning with melphalan/fludarabine, followed by …

Summary From 2002 to 2007, 49 myeloma patients who relapsed following autologous SCT
were included in a prospective multicenter trial to determine the efficacy of a reduced …

Allogeneic hematopoietic stem cell transplantation provides many patients, with
hematological and malignant diseases, hope of remission and in some cases cure. Because …

Relapse after dose-reduced allograft in advanced myeloma patients remains high. To
reduce the risk of relapse, we investigated a myeloablative toxicity-reduced allograft (aSCT) …

The purpose of this study was to determine long-term outcome of unrelated donor
nonmyeloablative hematopoietic cell transplantation (HCT) in patients with poor-risk multiple …

To evaluate trends in allografting from unrelated donors, we conducted a study on 196
consecutive myeloma patients transplanted between 2000 and 2009 in Italy. Twenty-eight …

Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapy for
patients with multiple myeloma, as it provides a graft-versus-myeloma effect alongside a …